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Abstract 
Hepatitis C virus (HCV) reactivation in patients receiving cancer treatment has been reported in 
retrospective studies. We sought to determine prospectively the incidence, predictors, and 
clinical significance of HCV reactivation during cancer treatment. HCV-infected patients 
receiving cancer treatment at our institution (11/2012-07/2016) were studied. Reactivation was 
defined as an increase in HCV-RNA ≥1 log10 IU/mL over baseline and hepatitis flare as alanine 
aminotransferase (ALT) increase to ≥3 times the upper limit of normal. One hundred patients 
were studied, 50 with hematologic malignancies and 50 with solid tumors. Reactivation occurred 
in 23 patients (23%), including 18 patients (36%) with hematologic malignancies and 5 (10%) 
with solid tumors. In univariate analysis, patients with reactivation were more likely than those 
without, to have prolonged lymphopenia (median, 95 vs 22 days, P=0.01) and to have received 
rituximab (44% vs 9%, P<0.0001), bendamustine (22% vs 0%, P<0.001), high-dose steroids 
(57% vs 21%, P=0.001), or purine analogs (22% vs 5%, P=0.02). Rituximab (odds ratio 
[OR]=9.52, P=0.001), and high-dose steroids (OR=5.05, P=0.01) retained significance in 
multivariable analysis. Of the 23 patients with reactivation, 10 (43%) had hepatitis flare. No 
patient with reactivation experienced liver failure or liver-related death within 36 weeks after 
initiation of cancer treatment. Fourteen patients with hepatitis flare of whom 6 had reactivation, 
required discontinuation or dose reduction of cancer treatment. Conclusions HCV reactivation 
occurred in 23% of HCV-infected patients receiving cancer treatment, and most had an 
unremarkable clinical course. However, reactivation can affect the cancer treatment plan.  Our 
findings suggest that HCV infection should not contraindicate cancer therapy and infected 
patients should have access to multiple cancer treatments with close monitoring while receiving 
regimens associated with HCV reactivation.  (Word count 275: word limit: 275)  
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Hepatitis C virus (HCV) infection is the most common blood-borne infection in the United 
States, where at least 3.5 million people are currently infected.(1) HCV infection is observed in 
1.5% to 32% of cancer patients around the world, depending on the geographic area and type of 
cancer studied.(2-5)  
 
Among patients with cancer receiving chemotherapy, liver dysfunction caused by hepatitis B 
virus (HBV) reactivation is a significant problem,(6-8) occurring in 14% to 72% of patients who 
did not receive prophylactic antiviral therapy and leading to liver failure in 13% of cases and 
death in 6% of cases.(6, 8-10) In contrast, the incidence and consequences of HCV reactivation 
(HCVr) during cancer treatment remain poorly defined. HCVr appears to be less common and to 
have less severe consequences than HBV reactivation;(3, 7, 11-13) with only a few fatal cases of 
fulminant hepatitis attributed to HCV having been reported.(14, 15) In a retrospective study of 
308 HCV-infected cancer patients, we observed that 11% experienced hepatitis flare during 
cancer treatment; however, the true incidence of HCVr could not be determined as HCV-RNA 
monitoring was not performed in many patients.(11) 
 
The use of chemotherapy in HCV-infected patients can be challenging.(5, 16) Oncologists 
extrapolate what is known about HBV reactivation and often exclude HCV-infected cancer 
patients from receiving many kinds of chemotherapy. For instance, approximately 48% of early-
phase cancer clinical trials at MD Anderson Cancer Center exclude HCV-infected patients. Thus, 
to fill the critical void in understanding of HCVr, we conducted this prospective observational 
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study to determine the incidence, predictors, and clinical significance of HCVr in patients 
receiving cancer treatment. 
 
MATERIALS AND METHODS 
Patients 
Cancer patients at least 18 years of age who were referred to the HCV clinic at The University of 
Texas MD Anderson Cancer Center from November 2012 through July 2016 and were scheduled 
to receive cancer treatment (chemotherapy [including targeted therapy] with or without 
radiotherapy) were enrolled in an observational study. Patients with hematologic malignancies or 
solid tumors were included. 
 
To avoid the confounding effect on liver chemistry tests caused by tumors infiltrating the liver, 
we excluded from our analysis patients with hepatocellular carcinoma or metastases in the liver 
(Figure 1). Patients with undetectable HCV-RNA were also excluded. 
 
Serum alanine aminotransferase (ALT) levels were measured regularly during cancer treatment. 
The MD Anderson HCV clinic protocol recommends quantifying serum HCV-RNA level before 
the initiation of chemotherapy, at 12-week intervals after initiation of cancer treatment, and at the 
time of hepatitis flare. The protocol for this observational study was approved by the MD 
Anderson Institutional Review Board. Written informed consent was obtained from each patient. 
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HCV-RNA quantification 
To measure HCV-RNA in serum, we used the COBAS AmpliPrep/COBAS TaqMan HCV test 
(version 2.0, Roche Molecular Systems, Branchburg, NJ) with a quantification range of 15 to 
100,000,000 IU/mL (1.18 log10 to 8.00 log10 IU/mL). HCV-RNA was measured during the 
routine follow-up of the patients in the clinic, irrespective of the cancer management. 
 
Chemotherapy regimens studied  
Only the last chemotherapy regimen was studied for each patient. However, if different 
chemotherapy regimen were given less than 3 months apart, we analyzed the cumulative effect 
of these regimens on HCVr. Patients receiving any type of cancer treatment, including 
maintenance chemotherapy, were included. 
 
Definitions 
As previously described,(11) we defined HCVr as an increase in HCV-RNA level of ≥ 1 log10 
IU/mL from baseline HCV-RNA following institution of cancer treatment; as chronically 
infected patients generally have stable HCV-RNA levels that vary within 0.5 log10 IU/mL.(17) 
 
Hepatitis flare was defined as an increase in ALT level to ≥ 3 times the upper limit of normal in 
the absence of liver infiltration by tumor, use of hepatotoxic drugs other than 
chemotherapeutics,(18) or other active systemic infection (bacterial or fungal infection or 
infection with hepatitis A virus, HBV, hepatitis E virus, or human immunodeficiency virus).  
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Lymphopenia was defined as an absolute lymphocyte count of 1,000 cells/µL or less. Duration 
of lymphopenia was measured from the start date of lymphopenia to the date of resolution of 
lymphopenia or 12 weeks after discontinuation of cancer treatment, whichever occurred first.  
 
Liver fibrosis was staged by liver biopsy in patients who had adequate platelets and normal 
coagulation, and who consented to the procedure. Cirrhosis was diagnosed on the basis of liver 
biopsy or a combination of clinical findings (e.g., ascites, encephalopathy, or jaundice), serum 
biomarker (Prometheus Fibrospect II [Prometheus Laboratories, San Diego, CA]), and radiologic 
findings (e.g., hepatic nodularity). As previously reported, acute liver failure in patients with 
chronic liver disease was defined as the development of jaundice (serum bilirubin level > 5 
mg/dL) and coagulopathy (international normalized ratio ≥ 1.5) complicated within 4 weeks by 
clinical ascites and/or encephalopathy.(19) 
 
High-dose steroids were defined as cumulative administration of the equivalent of > 600 mg of 
prednisone within 6 months after the start of cancer treatment. We divided chemotherapy 
regimens into the following subcategories: alkylating agents (cyclophosphamide, ifosfamide, 
melphalan, bendamustine, busulfan), platinum-containing agents (cisplatin, carboplatin, 
oxaliplatin), pyrimidine compounds (fluorouracil, capecitabine, cytarabine, gemcitabine, 
decitabine), purine analogs (mercaptopurine, fludarabine, cladribine, clofarabine), folate 
antagonists (methotrexate, pemetrexed), anthracyclines (daunorubicin, doxorubicin, epirubicin, 
idarubicin, bleomycin), topoisomerases (topotecan, etoposide, irinotecan), mitotic inhibitors 
(paclitaxel, docetaxel, vinblastine, vincristine), cytidine analogues (azacitidine, decitabine), 
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immunosuppressants (tacrolimus, cyclosporine), immunomodulatory drugs (lenalidomide, 
thalidomide), and tamoxifen. Targeted therapies other than rituximab (e.g., cetuximab, 
bortezomib, alemtuzumab) were grouped together.  
 
Outcomes 
Primary outcomes were the occurrence of HCVr and hepatitis flare from the start date of cancer 
treatment to 36 weeks (three clinic visits at 12-week follow-up interval) after the start date. 
Secondary outcomes were discontinuation or dose reduction of chemotherapy due to hepatitis 
flare, liver failure, and death within 36 weeks after the start of cancer treatment. 
 
Statistical analysis 
Patient characteristics were analyzed using descriptive statistics. We used chi-square or Fisher’s 
exact test to compare categorical variables and Wilcoxon-Mann-Whitney test to compare 
continuous variables. We used exact logistic regression analysis to determine independent 
predictors of HCVr. Spearman rank correlation test was used to assess the correlation between 
the changes (peak values minus baseline values) in HCV-RNA and ALT levels. All statistical 
tests were 2-sided and conducted using SPSS version 23.0 (IBM Corp., Armonk, NY). P < .05 
was considered statistically significant.  
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RESULTS 
Patient characteristics 
A total of 233 patients were enrolled, and 133 were excluded for various reasons (Figure 1), 
leaving 100 patients in this analysis. 
Of the 100 patients, 73 were men, and 61 were non-Hispanic white (Table 1). The median age 
was 59 years (IQR, 54-63). Fifty patients had hematologic malignancies, and 50 had solid 
tumors. Seventy-eight patients were infected with HCV genotype 1; of 71 patients tested, 44 had 
rs12979860 (formerly known as interleukin 28 B) genotype CT. Among 38 patients with liver 
biopsy performed, 15 (39%) had advanced liver disease (Metavir score F3 or F4). At enrollment, 
13 patients had cirrhosis (based on liver biopsy in 5 patients, and on a combination of clinical, 
laboratory or radiologic findings in 8 patients), and 70 patients were HCV treatment naïve.  Five 
patients received only maintenance chemotherapy, 4 only targeted therapy, and 2 only 
radiotherapy. 
 
Incidence of HCVr 
All 100 patients had HCV-RNA level measured at baseline, and 74 had HCV-RNA measured at 
least twice after cancer treatment initiation. In addition, 71 patients had HCV-RNA measured at 
least once during cancer treatment, and 87 patients had HCV-RNA measured at least once after 
cancer treatment. HCVr was detected in 23 patients (incidence, [95% confidence interval]; 23% 
[15% -31%]) in the entire cohort, including 18 (36%, [22% - 50%]) with hematologic 
malignancies and 5 (10%, [1% - 19%]) with solid tumors (Figure 2). The incidence of HCVr was 
highest among patients receiving regimens containing bendamustine (5/5, 100%), rituximab 
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(10/17, 59%), purine analogs (5/9, 56%), or high-dose steroids (13/29, 45%) (Table 2). Details 
on the 23 patients with HCVr are shown in table 3.  
Among the 74 patients with HCV-RNA measured at least twice after cancer treatment initiation, 
21 (28%, [18% - 39%]) had HCVr detected, including 18 of 40 (45%, [29% - 61%]) with 
hematologic malignancies and 3 of 34 (9%, [0% - 19%]) with solid tumors. When patients who 
received only maintenance chemotherapy, targeted therapy, or radiotherapy were excluded, 
HCVr was detected in 21 (32%, [20% - 44%]) of the remaining 65 patients, including 18 of 37 
(49%, [32% - 65%]) with hematologic malignancies and 3 of 28 (11%, [0% - 22%]) with solid 
tumors (Figure 2).  
 
Predictors of HCVr 
Compared to patients without HCVr, patients with HCVr were more likely to have hematologic 
malignancies (78% vs 42%, P = 0.002), particularly lymphoma (50% vs 22%, P = 0.05), lower 
baseline HCV RNA (median [IQR], 5.9 [5.3-6.2] vs 6.6 [6.1-6.9] log10 IU/mL, P < 0.0001), less 
frequent advanced liver disease by liver biopsy (15% vs 48%, P = 0.02) and to have received 
rituximab (44% vs 9%, P < 0.0001), high-dose steroids (57% vs 21%, P = 0.001), bendamustine 
(22% vs 0%, P < 0.001), or purine analogs (22% vs 5%, P = 0.02) (Table 4). Patients with HCVr 
also had lower lymphocyte nadir (median [IQR], 260 [30-530] vs 530 [210-1110] cells/µL, P = 
0.03), and more prolonged lymphopenia (95 [7-200] vs 22 [0-79] days, P = 0.01) after cancer 
treatment (Table 4). In multivariable analysis, only rituximab (odds ratio [OR] = 9.52, 95% CI = 
2.19-49.12, P = 0.001), and high-dose steroids (OR = 5.05, 95% CI = 1.40-20.23, P = 0.01) were 
significantly associated with HCVr (Table 5). 
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Factors associated with hepatitis flare in patients with HCVr 
Ten (43%) of the 23 patients with HCVr also had hepatitis flare (Figure 1). None of these 10 
patients were hepatitis B surface antigen positive. Two were positive for hepatitis B core 
antibody but both had undetectable HBV DNA. All 10 patients were also negative for human 
immunodeficiency virus, IgM antibodies to hepatitis A and hepatitis E, and cytomegalovirus 
DNA and herpes simplex virus DNA. None of these 10 patients had other causes of hepatitis 
flare such as a new malignancy infiltrating the liver, recent history of sepsis or parenteral 
nutrition, sinusoidal obstruction syndrome, or graft versus host disease. One patient received 
radiotherapy and chemotherapy, ALT decreased rapidly after decreasing dose of chemotherapy 
suggesting the possibility of drug-induced liver injury. Compared to the 13 patients without 
hepatitis flare, the 10 patients with hepatitis flare were more likely to have HCV genotype 2 
infection (40% vs 0%, P = 0.02), rs12979860 genotype CC (63% vs 22%, P = 0.15) and higher 
baseline ALT (median [IQR], 87 [71-120] vs 56 [29-75] IU/mL, P = 0.004), and were less likely 
to be black (0% vs 38%, P = 0.04) (supplementary table 1). Representative changes in ALT and 
HCV-RNA in a patient with HCVr and hepatitis flare are shown in Figure 3. 
 
Correlation between changes in HCV-RNA and ALT 
Changes in HCV-RNA and ALT were moderately correlated (r=0.47, P < 0.0001) 
(supplementary figure 1). Compared to patients without HCVr, patients with HCVr were more 
likely to have hepatitis flare (43% vs 16%, P = 0.006), higher peak ALT values (median [IQR], 
152 [111-395] vs 74 [52-126] IU/mL, P < 0.0001), and greater increases in median ALT from 
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baseline (78 [62-263] vs 22 [9-52] IU/mL, P < 0.0001) (Table 4). In patients with HCVr, serum 
HCV-RNA and ALT levels decreased after stopping cancer treatment. 
 
Clinical outcomes 
Fourteen patients (14%) required cancer treatment discontinuation and/or dose reduction due to 
hepatitis flare, 6 of 23 patients (26%) with and 8 of 77 (10%) without HCVr (P = 0.08). Among 
the 13 patients with cirrhosis, 5 patients (38%) had decompensation after starting cancer 
treatment. Two patients (2%) met the criteria for acute liver failure; but neither had HCVr. One 
patient had compensated cirrhosis (Child-Pugh score A) and cholangiocarcinoma without liver 
involvement. She received 3 cycles of gemcitabine plus cisplatin. The second patient did not 
have cirrhosis. He had myelodysplastic syndrome treated with single-agent decitabine 
complicated by pancreatitis and septic shock. Both patients had a decrease of HCV-RNA after 
start of chemotherapy. Liver decompensation was attributed to drug-induced liver injury in the 
first patient, and drug-induced liver injury, sepsis and shock in the second patient.  
 
Eight patients (8%) died within 36 weeks of starting cancer treatment, 3 of 23 (13%) with and 5 
of 77 (6%) without HCVr (P = 0.38). None of the 3 patients with HCVr had liver failure. Two of 
these 3 patients died of progressive cancer, and 1 died of progressive cancer and bacterial/fungal 
infection. 
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DISCUSSION  
To our knowledge, this is the first prospective study to examine the incidence, predictors, and 
clinical significance of HCVr in cancer patients receiving cancer treatment. We found that 23% 
of patients experienced HCVr and 43% of patients with HCVr also had hepatitis flare. The use of 
rituximab, high-dose steroids, bendamustine, and the purine analogs fludarabine or cladribine 
were associated with the development of HCVr, the risk being highest with rituximab or high-
dose steroids. Unlike HBV reactivation, HCVr seemed to have an indolent course. None of the 
patients with HCVr had liver failure or died of a liver-related cause but the oncologic 
consequences of HCVr remain to be determined as it can affect the cancer treatment plan.  
 
Most prior studies defined HCVr on the basis of abnormal ALT level without HCV-RNA 
data.(12, 20-22) Those studies left open the question whether the increase in ALT level was 
related to increase in HCV replication. In contrast, in our present analysis, we included only 
patients who had HCV-RNA measured. The HCVr incidence of 23% in the current study was 
lower than the incidence of 36% in our previous retrospective study.(11) However, our current 
and previous studies differed with respect to characteristics of the patients and tumors included 
and frequency of HCV-RNA monitoring. Therefore, the true incidence of HCVr remains to be 
confirmed.  
Approximately 50% of cases of HCVr in the current study were not accompanied by a 
significant increase in ALT and would have been missed without prospective monitoring of 
HCV-RNA levels. Fortunately, HCVr appeared to have a benign hepatic course, in agreement 
with the results of prior retrospective studies.(6, 11) Nevertheless, larger studies are needed to 
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confirm that HCVr does not result in liver-related outcomes. This is especially important because 
among hematopoietic cell transplant recipients and liver transplant recipients, 
immunosuppression has been clearly documented to result in accelerated progression of chronic 
liver disease and severe hepatocellular injury or fibrosing cholestatic hepatitis C in a small 
percentage of patients.(16, 23, 24)  
 
Our study also showed that HCVr necessitated discontinuation or dose reduction of potentially 
lifesaving chemotherapy in 26% of cases, which could negatively impact patients’ oncologic 
outcomes. Oncologist may hesitate to enroll HCV-infected patients into clinical trials due to the 
potential impact on cancer treatment plan. However, with the availability of multiple direct-
acting antiviral agents that are safe and can lead to virologic cure in >95% of patients with a 12-
week course of treatment, a case can be made to treat HCV first or simultaneous with cancer 
treatment particularly in patients with underlying advanced liver disease or are anticipated to 
receive regimens associated with HCVr such as rituximab or high-dose steroids.(25, 26) 
Alternately, HCV-infected patients can be closely monitored and antiviral treatment initiated 
after HCVr is detected. Prospective studies to test these approaches are warranted. Additional 
studies with longer follow-up are also needed to delineate the oncologic consequences of cancer 
treatment modifications in response to hepatitis flare associated with HCVr.  
 
Only the use of rituximab and high-dose steroids were significantly associated with high risk of 
developing HCVr. Rituximab as a single agent or in combination with steroids or other 
chemotherapeutic agents is the drug associated with the highest risk of HBV reactivation, in 
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persons with chronic or past HBV infection.(27) Rituximab had also been described to be an 
important cause of HCVr.(28, 29) Rituximab-based therapy causes a profound depletion of B 
cells and a marked reduction of T cells, mainly CD4+ cells, and has been reported to cause 
reactivation of other viruses, including cytomegalovirus and herpes simplex virus.(30, 31) In 
agreement with our previous retrospective study,(11) our current study confirmed that rituximab 
was associated with a high incidence of HCVr, more so when used in combination with high-
dose steroids. Steroids are known to cause a rapid depletion and apoptosis of circulating T cells. 
Previous studies revealed that steroids stimulate HCV replication in vitro,(32) and there are 
clinical reports that patients treated with high-dose steroids had an increase in HCV-RNA 
levels.(32, 33)  
 
Lymphopenia was associated with HCVr in univariate but not in multivariate analysis likely 
related to the small sample size. Bendamustine and selected purine analogs were also associated 
with HCVr in univariate analysis. Bendamustine causes a decline in CD4+ lymphocyte count 
that lasts for many months.(34) Reactivation of cytomegalovirus or HBV, but not of HCV, has 
been described with use of bendamustine.(35, 36) Purine analogs are also well known to induce 
profound and prolonged lymphopenia.(37) Strong CD4+ T-cell responses are associated with 
spontaneous HCV elimination.(38, 39) In addition, CD8+ depletion amplifies HCV 
replication.(40) HCV-infected patients receiving chemotherapy regimens with expected severe or 
prolonged lymphopenia might need closer observation for early detection of HCVr and hepatitis 
flare. 
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In the era of targeted therapy, our understanding of the effects of targeted agents on HCV 
replication is limited.(41) We found episodes of HCVr in patients receiving ruxolitinib, 
alemtuzumab, ofatumumab, ibrutinib, and bortezomib; however, except in the patient treated 
with ruxolitinib, the targeted therapies were given along with rituximab or high-dose steroids, 
which precluded conclusions about the direct effect of targeted agents on HCV replication. 
Ruxolitinib is an oral janus kinase (JAK) inhibitor. JAK-STAT signaling is essential for anti-
viral immunity.(42) Severe HBV reactivation has been reported with ruxolitinib therapy(43); 
however, to our knowledge, ours is the first report of HCVr after ruxolitinib. 
 
Certain chemotherapeutic agents are known to cause drug-induced liver injury and caution is 
recommended with their use in patients with preexisting liver fibrosis.(44) For instance, 
significant elevation of serum transaminases is reported in patients receiving anthracyclines 
(40%), taxanes (50%), vinca alkaloids (5-10%), methotrexate (15-50%), erlotinib (10%), 
pazopanib (50%), and ruxolitinib (25%).(45) Apart from ruxolitinib, none of these drugs was 
found to be associated with HCVr in our study. Moreover, among the patients who had a liver 
biopsy we observed a lower rate of HCVr in patients with advanced fibrosis stage, possibly 
because these patients were exposed to less immunosuppressive chemotherapy. This anomaly 
may also be related to spurious results due to small number of patients.  
 
All patients with HCVr who had HCV genotype 2 also had hepatitis flare. Previous studies have 
shown that patients with HCV genotype 2 are at higher risk of hepatitis flare than patients with 
other HCV genotypes.(46, 47) We also found that hepatitis flare was more likely to occur in 
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patients with HCVr having rs12979860 genotype CC. A strong association of rs12979860 
genotype CC with hepatic necroinflammation and increase in ALT level has been reported,(46)
, 
,
(48) suggesting that patients with genotype CC have a more robust immunologic response that 
leads to increased hepatic inflammation.(48) These factors associated with hepatitis flare may be 
clinically significant; however, because of the small number of such patients, no definite 
conclusions can be drawn.  
 
Our study has several limitations. First, patients had different types of cancer, and most patients 
received combinations of cancer treatment. This heterogeneity could affect the analysis of 
chemotherapy regimens (e.g., some regimens were only used for hematologic cancers), and limit 
our understanding of the impact of each agent. Second, the study was conducted at a tertiary 
cancer center, where many patients received multiple lines of chemotherapy and salvage 
chemotherapy. Therefore, our results may not be generalizable to cancer patients in the 
community. Third, not all patients had HCV-RNA tested per protocol and transient increase in 
HCV-RNA level might have been missed, resulting in underestimation of the incidence of 
HCVr. This study was observational in nature, HCV-RNA was measured during the routine 
follow-up of patients in the HCV clinic, irrespective of the administration of cancer treatment, 
not allowing to study the specific correlation between HCV-RNA levels and chemotherapy for 
all patients. Fourth, the duration of follow-up was short, and thus any case of late HCVr would 
have been missed. HBV reactivation associated with rituximab has been reported to occur up to 
18 months after the end of chemotherapy.(49) Fifth, having a control group of HCV-uninfected 
patients receiving chemotherapy would help in determining whether hepatitis flares are more 
common in HCV-infected patients. Sixth, 25 (25%) of patients in this study were positive for 
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hepatitis B core antibody and were at risk of HBV reactivation as potential explanation for 
hepatitis flare. However, all 21 who had HBV DNA checked before or during chemotherapy had 
undetectable HBV DNA. None of the four patients without HBV DNA measured had hepatitis 
flare during chemotherapy, received rituximab or underwent hematopoietic cell transplant. 
Finally, not all patients receiving chemotherapy at our institution were screened for HCV, and 
not all patients with HCV infection were referred to the HCV clinic; therefore, our study 
population may not be representative of all HCV-infected patients. 
 
In conclusion, HCVr occurred in 23% of patients with chronic HCV receiving cancer treatment 
and most had an unremarkable clinical course. Therefore, the potential risk of developing HCVr 
should not be considered a contraindication for chemotherapy. Our findings should help HCV-
infected cancer patients have a wide access to many types of chemotherapy, with close 
monitoring while receiving regimens associated with HCVr. Although hepatitis flares were 
observed, no patient had liver failure or died of a liver-related cause but hepatitis flare caused 
modification of cancer treatment, and such modification may have a negative impact on 
oncologic outcomes. Additional studies in larger patient populations with longer duration of 
follow-up are needed to fully delineate the incidence of HCVr, its predictors, and clinical 
consequences in cancer care. Given the availability of highly effective (90-95% cure rates in 
most series including patients with malignancies),(25) well-tolerated and short (8-12 weeks) 
courses of direct-acting antiviral combination therapies, HCV treatment can be initiated before or 
simultaneously with chemotherapy to optimize outcomes by avoiding changes in cancer 
treatment plan. 
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FIGURE LEGENDS 
Fig. 1. Flow diagram of HCV-infected cancer patients included in this study. 
Fig. 2. Incidence of HCV reactivation in different groups. 
Fig. 3. Description of a representative case with HCV reactivation and hepatitis flare. 
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Table 1. Characteristics of 100 Prospectively Studied HCV-Infected Cancer Patients 
Characteristic 
Number of Patients  
(%) 
Age at cancer treatment initiation, median (IQR), years 59 (54-63) 
Sex, male 73 (73) 
Race  
     Non-Hispanic 91 (91) 
         White 61 (67) 
         Black 26 (29) 
         Other* 4 (4) 
     Hispanic 9 (9) 
Cancer type  
     Hematologic 50 (50) 
     Solid 50 (50) 
Hematologic cancer type  
     Multiple myeloma 16/50 (32) 
     Leukemia 17/50 (34) 
     Lymphoma 16/50 (32) 
     Other
†
 1/50 (2) 
Solid cancer type  
     Gastrointestinal
‡
 15/50 (30) 
     Head and neck  10/50 (20) 
     Lung 10/50 (20) 
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     Breast 5/50 (10) 
     Melanoma 3/50 (6) 
     Other
§
 7/50 (14) 
HCV genotype  
     1 78/99 (78) 
     2 15/99 (15) 
     3 3/99 (3) 
     4 2/99 (2) 
     6 1/99 (1) 
rs12979860 genotype
¶
  
     CC 20/71 (28) 
     CT 44/71 (62) 
     TT 7/71 (10) 
HCV treatment naïve 70 (70) 
HBV coinfection  
     Anti-HBc positive 25/97 (26) 
      HBsAg positive 1/100 (1) 
HIV infection 0/97 (0) 
Cirrhosis at enrollment
||
 13 (13) 
Liver biopsy performed 38 
   Metavir score F1-F2 23 (61%) 
   Metavir score F3-F4 15 (39%) 
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Abbreviations: anti-HBc, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HBV, 
hepatitis B virus; HIV, human immunodeficiency virus; IQR, interquartile range.  
*Asian and Middle Eastern. 
†
Diamond-Blackfan anemia with hematopoietic cell transplant. 
‡
Colorectal cancer (n = 5), anal cancer (n = 3), esophageal cancer (n = 3), pancreatic cancer (n = 
2), cholangiocarcinoma (n = 1), and gastrointestinal stromal tumor (n = 1). 
§
Prostate (n = 2), gynecologic (n = 2), testicular (n = 1), urothelial (n = 1), and thyroid (n = 1). 
¶
Formerly
 
known as Interleukin-28B. 
||
Diagnosed on the basis of liver biopsy (n = 5) or radiologic and clinical findings (n = 8). 
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Table 2.  Incidence of HCVr and Median Change in HCV-RNA Level between Baseline and 
Peak According to Cancer Type and Cancer Treatment Regimen 
Cancer type or drugs received 
HCVr incidence 
rate  
95% confidence interval 
for the estimated HCVr 
incidence rate 
Median Change in 
HCV-RNA Level, 
log10 IU/mL (IQR) 
All patients 23/100 (23%) 15% – 31% 0.2 (-0.1 – 0.82) 
Cancer type    
   Hematologic 18/50 (36%) 22% – 50% 0.44 (-0.14-1.10) 
   Solid 5/50 (10%) 1% – 19 % 0.04 (-0.32-0.39) 
Drugs received    
   Rituximab 10/17 (59%) 33% - 85% 1.05 (0.47-1.22) 
   High-dose steroid 13/29 (45%) 26% - 64% 0.54 (-0.12-1.43) 
   Alkylating agent* 9/29 (31%) 13% - 48% 0.35 (-0.07-1.06) 
      Cyclophosphamide or ifosfamide 3/17 (18%)  0.35 (-0.16-0.75) 
      Melphalan 3/12 (25%)  0.1 (-0.24-.25) 
      Bendamustine 5/5 (100%)  1.23 (1.13-2.0) 
  Platinum
†
 3/32 (9%) 0 – 20% -0.09 (-0.37-0.33) 
  Antimetabolite 11/40 (28%) 13% - 42% 0.25 (-0.38-1.05) 
      Pyrimidine compound
‡
 9/32 (28%)  0.33 (-0.35-1.05) 
      Purine analog
§
 5/9 (56%)  0.96 (0.11-1.36) 
      Folate antagonist
¶
 2/7 (29%)  0.39 (-0.14-0.39) 
  Anthracyclin
||
 4/13 (31%) 2% - 60% 0.35 (-0.04-0.75) 
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 Topoisomerase** 2/8 (25%) 0 – 63% -0.01 (-0.37-0.71) 
 Mitotic inhibitor
††
 3/20 (15%) 0 – 32% 0.27 (-0.34-0.75) 
 Monoclonal antibody
‡‡
 7/22 (32%) 11% - 53% 0.37 (-0.04-1.10) 
*Cyclophosphamide, ifosfamide, melphalan, bendamustine, busulfan. 
†
Cisplatin, carboplatin, or oxaliplatin. 
‡
Fluorouracil, capecitabine, cytarabine, gemcitabine, or decitabine. 
§
Mercaptopurine, fludarabine, cladribine, or clofarabine. 
¶
Methotrexate or pemetrexed. 
||
Daunorubicin, doxorubicin, epirubicin, idarubicin, or bleomycin. 
**Topotecan, etoposide, or irinotecan. 
††
Paclitaxel, docetaxel, vinblastine, or vincristine. 
‡‡
Cetuximab, ruxolitinib, trastuzumab, bortezomib, carfilzomib, bevacizumab, dasatinib, 
ipilimumab, dabrafenib, trametinib, vismodegib, alemtuzumab, ofatumumab, pazopanib, or 
regorafenib. 
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Table 3.  Description of the 23 Patients with HCVr. 
Patient  Age Gender Cirrhosis Type of Cancer Chemotherapy regimen 
HCV-RNA 
change 
(log10IU/ml) 
Peak of 
ALT 
(U/L) 
Peak of 
bilirubin 
(mg/dL) 
Peak of 
INR 
1 53 Female No MM 
Bortezomib, cyclophosphamide,  
lenalidomide + HDS 
1.08 134 1.1 1.12 
2 80 Female No MM Thalidomide 2.86 241 1 1.03 
3 63 Male No MM Gemcitabine, busulfan, melphalan + HDS 1.58 124 8.8* 2.53* 
4 69 Male No WM R- bortezomib 1.12 69 0.7 1.09 
5 57 Male No DLBCL R-gemcitabine, and ofatumumab 1.1 395 1.1 1.05 
6 53 Male No DLBCL 
R-lenalidomide followed by R-
bendamustine, fludarabine, methotrexate 
1.21 111 1.2 1.08 
7 59 Male No DLBCL R-CHOP followed by R-ICE 1.0 252 1.4 1.1 
8 25 Male No DLBCL 
R-ICE  followed by R-vorinostat, 
gemcitabine, busulfan, melphalan 
1.99 539 8.3 1.25 
9 70 Male No FL R-bendamustine 2.39 1160 14 1.32 
10 61 Female No MZL R-bendamustine 1.05 66 0.8 1.03 
11 65 Male No MCL R-ibrutinib 1.1 137 0.7 1.12 
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Abbreviations: 5-FU, fluorouracil; AML, acute myeloid leukemia; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; 
CLL, chronic lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HDS, high dose steroids; 
ICE, ifosfamide, carboplatin, etoposide; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MZL, marginal zone 
lymphoma;  N/A, not available; R, rituximab; WM, waldenstrom's macroglobulinemia. 
52 Male No MCL 
R-bendamustine followed by R-
fludarabine, melphalan, methotrexate 
1.62 163 2.7 1.27 
62 Male Yes AML Cladribine, idarubicin, cytarabi ne + HDS 1.52 138 1.6 1.22 
57 Female No AML Cytarabine, idarubicin, clofara bine + HDS 1.0 888 1.8 1.24 
57 Male No AML 
Decitabine followed by cladribine, 
idarubicin, and cytarabine 
2.08 247 7.9* 1.68* 
62 Male Yes CLL Alemtuzumab + HDS 1.35 152 1.8 1 .12 
63 Male Yes CLL R-bendamustine 1.23 104 1.5 1.23  
69 Male No MDS HDS followed by cyclosporine 1.68  349 6 1.07 
41 Female No Esophageal  Docetaxel, 5-FU, oxalip latin, HDS 2.96 46 0.5 1.32 
54 Male No Gastroesophageal  Docetaxel, 5-FU + HDS 1.52 453 0.9 0.98 
56 Male No Anal  Mitomycin, 5-FU 1.09 78 0.7 1.0 5 
61 Male No Germ cell Ruxolitinib 1.38 134 0.8 1. 14 
56 Male No Melanoma Ipilimumab followed by HDS 1 .43 493 0.9 1.13 
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*Both patients did not have clinical ascites and/or encephalopathy and thus did not fulfill the Asian Pacific Association for the Study 
of the Liver (APASL) criteria for acute liver failure in patients with chronic liver disease.
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Table 4. Characteristics of Patients with and without HCVr 
Characteristic 
No. (%) of 
Patients with 
HCVr 
(n = 23) 
No. (%) of  
Patients without 
HCVr 
(n = 77) P 
Age at initiation of cancer treatment in years, median 
(IQR), years 
58 (54-63) 59 (54-63) 0.88 
Male 18 (78) 55 (71) 0.51 
White 16 (70) 45 (59) 0.46 
Hematologic cancer 18 (78) 32 (42) 0.002 
     Lymphoma 9/18 (50) 7/32 (22) 0.005 
HCV      0.56 
    Genotype 1 17 (74) 61 (80)  
    Non-Genotype 1 6 (26) 15 (20)  
rs12979860*      0.21 
     Genotype CC 7/17 (41) 13/54 (24)  
     Non-Genotype CC 10/17 (59) 41/54 (76)  
HBcAb positive 5/23 (22) 20/74 (27) 0.61 
     HBV DNA detected 0/4 0/18  
Cirrhosis at enrollment 3 (13) 10 (13) >0.99 
Liver biopsy, Metavir score F3-F4 2/13 (15%) 13/25 (52%) 0.02 
Chemotherapy 23 (100) 72 (94) 0.58 
Radiotherapy 2 (9) 17 (22) 0.22 
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Hematopoietic cell transplant 3 (13) 6 (8) 0.42 
Drugs received      
  Rituximab 10 (44) 7 (9) <0.0001 
     Rituximab cumulative dose, median (IQR), mg 3894 (2987-5068) 2950 (1850-4584) 0.48 
  High-dose steroid 13 (57) 16 (21) 0.001 
     Steroid cumulative dose, median (IQR), mg 850 (250-1425) 488 (300-700) 0.10 
  Alkylating agent
†
 9 (39) 20 (26) 0.22 
     Cyclophosphamide or ifosfamide 3 (13) 14 (18) 0.75 
     Melphalan 3 (13) 9 (12) >0.99 
     Bendamustine 5 (22) 0 <0.0001 
     Busulfan 2 (9) 2 (3) 0.23 
  Platinum
‡
 3 (13) 29 (38) 0.02 
  Antimetabolite 11 (48) 28 (36) 0.38 
     Pyrimidine compound
§
 9 (39) 23 (30) 0.40 
     Purine analog
¶
 5 (22) 4 (5) 0.02 
     Folate antagonist
||
 2 (9) 5 (7) 0.65 
  Anthracyclin** 4 (17) 9 (12) 0.48 
  Topoisomerase
††
 2 (9) 6 (8) >0.99 
  Mitotic inhibitor
‡‡
 3 (13) 17 (22) 0.55 
  Monoclonal antibody
§§
 7 (30) 15 (20) 0.26 
  Immunosuppressant (tacrolimus or cyclosporine) 1 (4) 1 (1) 0.40 
  Cytidine analogue (azacitidine or decitabine) 1 (4) 4 (5) >0.99 
  Immunomodulatory drug
¶¶
 3 (13) 4 (5) 0.19 
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  Tamoxifen 0 4 (5) 0.57 
Baseline HCV-RNA, median (IQR), log10 IU/mL 5.9 (5.3-6.2) 6.6 (6.1-6.9) <0.0001 
ALT, IU/mL      
     Baseline, median (IQR) 71 (53-88) 52 (32-69) 0.04 
     Peak, median (IQR) 152 (111-395) 74 (52-126) <0.0001 
Lymphopenia 21 (91) 49 (64) 0.01 
Nadir lymphocyte count, median (IQR), cells/µL 260 (30-530) 530 (210-1110) 0.03 
Duration of lymphopenia, median (IQR), days 95 (7-200) 22 (0-79) 0.01 
Hepatitis flare 10 (43) 12 (16) 0.006 
Cancer treatment discontinuation or dose reduction 
due to hepatitis flare 
6 (26) 8 (10) 0.08 
Liver failure  0 2 (3) >0.99 
Death within 36 weeks of peak HCV-RNA
||||
 3 (13) 5 (6) 0.38 
Abbreviations: HbcAb, hepatitis B core antibody; HbsAg, hepatitis B surface antigen; IQR, 
interquartile range. 
*Formerly
 
known as Interleukin-28B. 
†
Cyclophosphamide, ifosfamide, melphalan, bendamustine, or busulfan. 
‡
Cisplatin, carboplatin, or oxaliplatin. 
§
Fluorouracil, capecitabine, cytarabine, gemcitabine, or decitabine. 
¶
Mercaptopurine, fludarabine, cladribine, or clofarabine. 
||
Methotrexate or pemetrexed. 
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**Daunorubicin, doxorubicin, epirubicin, idarubicin, or bleomycin. 
††
Topotecan, etoposide, or irinotecan. 
‡‡
Paclitaxel, docetaxel, vinblastine, or vincristine. 
§§
Cetuximab, ruxolitinib, trastuzumab, bortezomib, carfilzomib, bevacizumab, dasatinib, 
ipilimumab, dabrafenib, trametinib, vismodegib, alemtuzumab, ofatumumab, pazopanib, or 
regorafenib. 
¶¶
Thalidomide, lenalidomide, or pomalidomide.
 
||||
Cause of
 
death were progressive cancer (n = 4), bacterial/fungal pneumonia and progressive 
disease (n = 4), and unknown (n = 4). 
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Table 5. Exact Logistic Regression Analysis for Predictors of HCV Reactivation* 
Potential Predictor OR 95% CI P Value 
High-dose steroids (>600 mg equivalent prednisone vs < 600 mg) 5.05 1.40-20.23 0.01 
Rituximab use (yes vs no) 9.52 2.19-49.12 0.001 
Baseline HCV-RNA (> 6 log10 IU/mL vs < 6 log10 IU/mL) 0.12 0.03-0.46 <0.001 
*All variables with P < .2 in univariate analysis were included in the model (steroid use, 
rituximab use, platinum use, purine compound use, bendamustine use, type of malignancy [solid 
vs hematologic], baseline HCV-RNA level, nadir of lymphopenia, and duration of lymphopenia). 
Liver fibrosis stage by liver biopsy was not included because only 38 patients underwent liver 
biopsies. 
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Supplementary Table 1.  Comparison of Patients with HCVr and Hepatitis Flare to Those with HCVr and 
without Hepatitis Flare. 
Characteristic 
No. (%) of Patients 
with HCVr and 
Hepatitis Flare 
(n = 10) 
No. (%) of Patients 
with HCVr without 
Hepatitis Flare 
 (n=13)  P 
Age in years, median (IQR) 57 (55-69) 61 (53-63) 0.95 
Sex, male 8 (80) 10 (77) >0.99 
Race    
     White 8 (80) 8 (62) 0.40 
     Black 0 5 (38) 0.04 
     Hispanic 1 (10) 0 0.43 
     Asian 1 (10) 0 0.43 
Type of cancer, hematologic cancers 8 (80) 10 (77) >0.99 
HCV genotype    
    1 5 (50) 12 (92) 0.05 
    2 4 (40) 0 0.02 
    4 0 1 (8) >0.99 
    6 1 (10) 0 >0.99 
rs12979860 genotype*    
    CC 5/8 (63) 2/9 (22) 0.15 
    CT 2/8 (25) 6/9 (67) 0.15 
    TT 1/8 (13) 1/9 (11) >0.99 
Cirrhosis 0 4 (31) 0.10 
Liver fibrosis    
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   Liver biopsy, Metavir score F3-F4 1/5 (20) 1/8 (12) >0.99 
Hematopoietic cell transplant  0 3 (23) 0.22 
Drugs received    
    Rituximab containing 4 (40) 6 (46) >0.99 
    High dose steroids 6 (60) 7 (54) >0.99 
    Alkylating  agents† 3 (30) 6 (46) 0.66 
    Platinum ‡ 2 (20) 1 (8) 0.56 
    Antimetabolite§ 5 (50) 6 (46) >0.99 
    Anthracyclin¶ 3 (30) 1 (8) 0.28 
    Topoisomerase || 2 (20) 0 0.17 
    Mitotic inhibitor** 2 (20) 1 (8) 0.56 
    Monoclonal Antibody†† 2 (20) 5 (39) 0.40 
    Tacrolimus 1 (10) 0 0.43 
HCV RNA (log10IU/mL)    
   Baseline HCV RNA, median (IQR) 5.8 (5.1 - 6.2) 6.0 (5.3 - 6.3) 0.66 
   Peak RNA, median (IQR) 7.4 (6.9 - 7.7) 7.1 (6.7 - 7.6) 0.42 
   Change RNA, median (IQR) 1.6 (1.0 - 2.1) 1.2 (1.0 - 1.5) 0.29 
Absolute lymphocyte count (cells/ µL)    
   Nadir lymphocyte, median (IQR) 240 (20 - 730) 310 (50 - 550) 0.95 
   Drop of Lymphocyte, median (IQR) 1140 (330 - 1650) 1110 (750 - 1680) 0.49 
   Duration of Lymphopenia, median (IQR) 124 (26 - 205) 53 (5 - 199) 0.49 
Baseline ALT (IU/mL) 87 (71-120) 56 (29-75) 0.004 
Abbreviations: HCVr, HCV reactivation; HbcAb, hepatitis B core antibody; HbsAg, hepatitis B surface antigen; 
IQR, interquartile range;  
*Formerly known as Interleukin-28B. 
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†Cyclophosphamide, ifosfamide, melphalan, bendamustine, or busulfan. 
‡Cisplatin, carboplatin, or oxalaplatin. 
§Fluorouracil, capecitabine, cytarabine, gemcitabine, decitabine, Mercaptopurine, fludarabine, cladribine, 
clofarabine, methotrexate, or pemetrexed. 
¶Daunorubicin, doxorubicin, epirubicin, idarubicin, or bleomycin. 
||Topotecan, etoposide, or irinotecan. 
**Paclitaxel, docetaxel, vinblastine, or vincristine. 
††Cetuximab, ruxolitinib, trastuzumab, bortezomib, carfilzomib, bevacizumab, dasatinib, ipilimumab, 
dabrafenib, trametinib, vismodegib, alemtuzumab, ofatumumab, pazopanib, or regorafenib. 
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Supplementary Figure 1. Correlation between changes in HCV-RNA and ALT. 
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